Clinical Trials Logo

Graft vs Host Disease clinical trials

View clinical trials related to Graft vs Host Disease.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT03172455 No longer available - Clinical trials for Graft Vs Host Disease

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Start date: n/a
Phase:
Study type: Expanded Access

An Early Access Program for patients with steroid refractory acute GvHD after hematopoietic stem cell transplantation. This Program is available for female and male who are recipients of allogenic HSCT and who have been newly diagnosed with acute GvHD.

NCT ID: NCT02026934 No longer available - Clinical trials for Delayed Graft Function

CliniMACS® CD34+ Reagent System for Expanded Access Use

Start date: March 2013
Phase: N/A
Study type: Expanded Access

CliniMACs is an investigational device used to select and enrich stem cells. The device will select the stem cells with CD34+ protein. The participant will be infused with the CD34+ selected cells in the hopes that it will help the participant engraft. Engraftment is when transplanted stem cells resume production of healthy blood cells.

NCT ID: NCT00826046 No longer available - Clinical trials for Graft-Versus-Host Disease

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

Start date: n/a
Phase:
Study type: Expanded Access

This protocol allows for the treatment of patients, male and female, between the ages of 18 years and 70 years. Patients must have failed to respond to steroid treatment for Grade C-D acute GVHD.

NCT ID: NCT00759018 No longer available - Clinical trials for Graft vs Host Disease

Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD

Start date: n/a
Phase:
Study type: Expanded Access

This protocol allows for the treatment of pediatric patients, male and female, between the ages of 2 months and 17 years. Patients must have failed steroid treatment for Grade B-D acute GVHD.